With broad-based growth across all businesses and regions during the quarter, CZM reported a 9.6% upsurge in the top-line on an underlying basis. However, currency played spoilsport and lowered the revenue growth to 3.7%. Profitability was also under pressure, impacted by unfavourable product mix and increased investments into R&D. However, with a growing proportion of high margin recurring revenue in the total sales mix, we expect the margin to improve from here on.
16 May 2018
Revenue in line but profitability underperforms slightly
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Revenue in line but profitability underperforms slightly
Carl Zeiss Meditec AG (AFX:WBO) | 0 0 1.8% | Mkt Cap: 4,494m
- Published:
16 May 2018 -
Author:
Sumit Sayal -
Pages:
3
With broad-based growth across all businesses and regions during the quarter, CZM reported a 9.6% upsurge in the top-line on an underlying basis. However, currency played spoilsport and lowered the revenue growth to 3.7%. Profitability was also under pressure, impacted by unfavourable product mix and increased investments into R&D. However, with a growing proportion of high margin recurring revenue in the total sales mix, we expect the margin to improve from here on.